OLIPASS CORPORATION
KOSDAQ-listed RNA therapeutics biotech developing its non-opioid analgesic OLP-1002 on the OliPass PNA (OPNA) platform, out-licensed to Vanda Pharmaceuticals and others.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2006 and listed on KOSDAQ in 2019, OLIPASS is a biotech specializing in RNA therapeutics platforms. Through its proprietary OliPass PNA (OPNA) technology, it binds pre-mRNA to suppress the production of specific proteins via an exon-skipping mechanism, and its lead pipeline candidate, the non-opioid analgesic OLP-1002 (targeting the SCN9A gene), has completed a UK Phase 1 trial and Australian Phase 1b and Phase 2a (stages 1 and 2) trials. In September 2022, it signed a joint R&D agreement with NASDAQ-listed Vanda Pharmaceuticals Inc. for rare-disease and immuno-oncology therapeutics with an upfront payment of USD 3 million, and in August 2022 it out-licensed a respiratory antiviral therapeutic to Gifted MS Co., Ltd. for an upfront payment of KRW 1 billion plus milestone royalties of 5-50% and running royalties of 2-12.5%.
R&D and key agreements
Source: DART corporate disclosureOLP-1002 · 통증(관절염·비마약성 진통) · 호주 임상2a상 1·2단계 완료(Sponsor Audit 진행중, 2024.12 기준) · RNA analgesic targeting the SCN9A gene to selectively inhibit the Nav1.7 sodium channel
OliPass PNA(OPNA) 플랫폼 · 플랫폼 기술 · Proprietary RNA therapeutics platform using pre-mRNA binding and exon skipping
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition